A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Inclusion Criteria:

• Have type 2 diabetes

• Are on stable treatment for type 2 diabetes for at least 90 days prior to screening

• Have a BMI ≥ 27 kg/m2

• Have a stable body weight (<5% body weight change) for 90 days prior to screening

Exclusion Criteria:

• Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis,or abdominoplasty allowed if performed >1 year before screening)

• Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 monthsprior to screening)

• Have type 1 diabetes

• Have taken any of the following antihyperglycemic medications within 90 days beforescreening:

• amylin analogs

• glucagon-like peptide-1 (GLP-1) receptor agonists

• glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP)receptor agonists, or

• insulin

• Have had within 90 days prior to screening:

• heart attack

• stroke

• coronary artery revascularization

• unstable angina, or

• hospitalization due to congestive heart failure

• Have a history or diagnosis of New York Heart Association Functional ClassificationClass IV congestive heart failure

• Have taken medications or alternative remedies intended for weight loss within 90days of screening